PEGPH20 add-on therapy × increased objective response — evidence sheet for a lower-order endpoint under fixed-sequence testing

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Comparative efficacyAre the original objective-response subclaim verdict and parent survival grade D distinguished?Required	The selected existing claim is increased objective response, original grade C. Its note states 47% versus 36%, but no eligibility for confirmatory testing under the fixed sequence. The parent is OS D34 with Caution. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Absent subclaim scores, statuses and axes are not filled with parent values. Subclaim C is not uniformly changed to D, and no new grade is assessed.	Separate records of subclaim original wording, grade, note and parent context	Proposal: Link additional materials separately to the response question and parent survival results.
2	Partly verified	Full text not readStored summary read	N02 · Comparative efficacyWho was actually eligible for response-rate analysis?Required	The original population was untreated stage IV pancreatic ductal adenocarcinoma with stromal hyaluronan staining of at least 50%. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not automatically apply this to responses at other expression levels, cancers, treatment lines or stages. Additional response-analysis eligibility and assessable populations remain unread.	Expression, cancer type, stage, treatment line, baseline conditions and denominators	Proposal: Obtain original eligibility, baseline tumor, biomarker and assessable analysis-population materials.
3	Partly verified	Full text not readStored summary read	N03 · Comparative efficacyWere added PEGPH20, matching placebo and shared anticancer treatment separated?Required	The trial context of nab-paclitaxel plus gemcitabine in both groups, with added PEGPH20 versus matching placebo, is preserved. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Original response effects are not converted into overall efficacy of shared anticancer treatment. Dose, schedule, actual exposure and discontinuation details remain unread; no treatment guidance is created.	Original drug, placebo, shared-treatment and actual-exposure records	Proposal: Obtain original intervention, placebo, shared regimen and actual-exposure materials.
4	Partly verified	Full text not readStored summary read	N04 · Comparative efficacyAre shared thrombosis-prophylaxis conditions and actual management scope retained?Required	Both groups had mandatory enoxaparin prophylaxis because of thromboembolic risk. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Research conditions are not converted into prophylactic-medication instructions for readers. Response or safety results are not automatically applied to other conditions without prophylaxis.	Prophylaxis, concomitant management, actual exposure, adherence and denominators	Proposal: Obtain original shared-management, prophylactic-exposure, deviation and group-specific event materials.
5	Partly verified	Full text not readStored summary read	N05 · Comparative efficacyAre 494 randomized participants, 492 ITT participants and response-rate denominators the same?Required	494 participants randomized 2:1 and 492 ITT participants are overall trial information. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. 492 is not certified as a response-analysis denominator that was not directly given. Group-specific denominators and responder counts are not back-calculated from proportions.	Group-specific allocation, ITT, assessable-imaging and response-analysis denominators	Proposal: Obtain original group allocation, response-analysis populations, assessable counts and original responder tables.
6	Unverified	Full text not readStored summary read	N06 · Comparative efficacyWhat were objective-response criteria, confirmation, times and assessors?Required	The preserved summary records objective imaging response as a separate lower-order outcome. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. RECIST version, central or institutional assessment, complete or partial response, confirmation schedules and classification methods are absent from the summary and are not created.	Imaging criteria, response types, confirmatory assessments, times and measurement procedures	Proposal: Obtain original response definitions, assessment procedures, assessors, schedules and classification tables.
7	Partly verified	Full text not readStored summary read	N07 · Comparative efficacyWere original proportions of 47% versus 36% and missing original responder counts retained?Required	Objective response of 47% versus 36% is recorded in the original summary body. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not calculate new proportion differences, responder counts, NNT or RR. Group labels, original denominators and missing-assessment handling details remain unread.	Original group-specific proportions, responders, denominators and aggregation rules	Proposal: Obtain original responders, group-specific analysis denominators and aggregation rules.
8	Partly verified	Full text not readStored summary read	N08 · Comparative efficacyAre the response ratio 1.29, CI and new tests distinguished?Required	The original response ratio is 1.29 (95% CI 1.03 to 1.63). R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not recalculate from 47/36 or create the ratio model, new P, exact tests, adjustment variables or inferential eligibility.	Original ratio, CI, testing, model, denominator and effect definitions	Proposal: Obtain original ratio definitions, models, intervals, denominators and testing plans.
9	Partly verified	Full text not readStored summary read	N09 · Comparative efficacyWas the fixed sequence requiring significant survival first preserved?Required	The preserved summary states that overall survival had to be significant first for lower-order confirmatory testing, and response must be interpreted as exploratory after survival failed. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Exclusion of 1 by the CI alone does not promote response into prespecified confirmatory success.	Original plans for testing sequence, alpha, endpoint hierarchy and changes	Proposal: Obtain original SAP, fixed sequence, alpha, testing and outcome lists.
10	Partly verified	Full text not readStored summary read	N10 · Comparative efficacyAre the prespecified 2019 amendment, sole primary overall survival and response hierarchy distinguished?Required	The summary records OS as the sole primary endpoint after the prespecified 2019 amendment and states agreement with NCT02715804. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Response is not newly designated as coprimary. Earlier hierarchy, amendment circumstances and actual registration content remain unread.	Registration, protocol, SAP, dates and decisions before and after amendment	Proposal: Obtain original registration history, amendment events, protocol and SAP separately.
11	Partly verified	Full text not readStored summary read	N11 · Comparative efficacyWere exploratory response signals, clinical importance and confirmatory effects separated?Required	The preserved summary recognizes improved response itself while stating that it is not a confirmatory conclusion or equivalent to survival benefit. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not create clinical-importance thresholds, confirmatory response success or universal treatment benefit absent from the original summary.	Response importance, prespecified success thresholds, hierarchy and original CI	Proposal: Obtain original planned importance, response maintenance, clinical links and hierarchy.
12	Partly verified	Full text not readStored summary read	N12 · Comparative efficacyWere null overall survival and increased response preserved together?Required	For 492 ITT participants, OS of 11.2 versus 11.5 months, HR 1.00 (95% CI 0.80 to 1.27), P=.97 and 330 deaths are preserved. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Imaging response is not transferred into prolonged OS. The original context that the OS CI retained possible benefit is also not erased.	Original OS medians, HR, CI, P, events and denominators	Proposal: Obtain original OS models, curves, censoring, group-specific events and denominators separately.
13	Partly verified	Full text not readStored summary read	N13 · Comparative efficacyAre null progression-free survival, response duration and progression the same outcome?Required	Median PFS of 7.1 versus 7.1 months, HR 0.97 (95% CI 0.75 to 1.26), is preserved. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Positive response is not converted into PFS or response-duration benefit. Response duration, progression times and PFS P remain unread.	PFS, response duration, imaging-response definitions, effects and denominators	Proposal: Obtain original PFS, response-duration, persistence and progression definitions and tables.
14	Partly verified	Full text not readStored summary read	N14 · Comparative efficacyWere central allocation, double-blinding and imaging-assessment details separated?Required	Central interactive-response-system allocation and double-blinding with matching placebo appear in the preserved summary. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. This information alone does not constitute new verification of central imaging assessment, independent assessors or analyst blinding.	Original allocation-concealment, blinding, imaging-assessor and analyst methods	Proposal: Obtain original allocation, imaging-assessment, blinding roles and unblinding procedures.
15	Unverified	Full text not readStored summary read	N15 · Comparative efficacyWere gaps in missing response assessments, deviations, progression, death handling and denominators retained?Required	Overall ITT information and original response proportions exist, but detailed response-assessment data flow is absent from the summary. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Proportions alone do not establish complete imaging for all patients, death or progression handling or ITT response rules.	Missing imaging assessments, analysis populations, deaths, progression and missing-data rules	Proposal: Obtain original assessable populations, reasons for missing assessments, death or progression handling, missing-data handling and sensitivity materials.
16	Unverified	Full text not readStored summary read	N16 · Comparative efficacyWhat gaps remain in response interpretation of actual exposure, anticancer intensity, discontinuation or subsequent treatment?Required	Historical intervention, shared anticancer treatment and mandatory prophylaxis conditions are preserved. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not newly calculate responder-specific exposure, dose intensity, discontinuation or subsequent-treatment effects absent from the original summary.	Added drug, shared anticancer treatment, prophylaxis, crossover, discontinuation and actual exposure	Proposal: Obtain original exposure, discontinuation, subsequent management and prespecified effect-of-interest materials.
17	Unverified	Full text not readStored summary read	N17 · Comparative efficacyWere response subgroups, expression analyses and multiple outcomes verified prospectively?Required	The selected population's staining threshold of at least 50% and lower-order response plans are preserved in the summary. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. No additional expression strata, treatment lines, subgroup response counts, P or independent success are created.	Original plans for subgroups, interactions, hierarchy, denominators and testing	Proposal: Obtain original subgroup, biomarker, interaction, multiplicity and effect materials.
18	Partly verified	Full text not readStored summary read	N18 · Comparative efficacyWere mechanisms and imaging shrinkage not converted into clinical function or survival benefit?Required	The preserved summary explicitly states that imaging response must not be promoted into survival benefit. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Mechanistic, pain, quality-of-life, independent-living or mortality benefits are not filled in from response rates. These direct values are absent from the summary.	Separate materials for response, mechanisms and direct clinical function or survival	Proposal: Obtain direct endpoints, effects and denominators separately for clinical-function, symptom and survival questions.
19	Partly verified	Full text not readStored summary read	N19 · Comparative efficacyWere the same HALO report, cohort and two endpoints not added as independent evidence?Required	The two sheets share one HALO109-301 literature record, NCT02715804 and the 494/492-participant context. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Response, OS, PFS and sibling sheets are not added as new independent trials or participants. Final independent and total-participant counts remain unrecorded.	Relationships among original trial, report, shared participants, times and sibling sheets	Proposal: Link new reports to existing trial and registration identifiers and relationships.
20	Partly verified	Full text not readStored summary read	N20 · Comparative efficacyWere Halozyme support, drug or placebo, 2 employees and Paragon writing separated?Required	Halozyme sponsorship and support, protocol, drug or placebo, data management, 2 company authors and Paragon medical writing paid by Halozyme are preserved. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Paragon writing is not converted into outsourced analysis. Employee identities, statistical-analysis and data-access role details remain unread.	Cash support, products, affiliations, management and external analysis or writing roles	Proposal: Obtain each support, supply, affiliation, analysis, management and writing disclosure.
21	Partly verified	Full text not readStored summary read	N21 · Comparative efficacyWere original R1 and I0 and unverified independent replication retained?Required	Parent R1 and I0 and the original wording that the confirmed efficacy trial was one manufacturer development trial are retained. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Positive response or two outcomes do not certify independent replication by other investigators or funding sources.	Relationships among manufacturer trial, funding, investigators and original verdict	Proposal: Link study, funding, author and denominator relationships of additional materials separately.
22	Partly verified	Full text not readStored summary read	N22 · Supplementary harm evidenceAre grade 3 or worse harm proportions and response benefit displayed separately?Required	Original grade 3 or worse proportions are preserved: fatigue 16.0% versus 9.6%, muscle spasms 6.5% versus 0.6% and hyponatremia 8.0% versus 3.8%. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not create responder-specific harm counts, new differences, RR, CI or P. Safety-analysis denominators, periods and relatedness remain unread.	Original group-specific safety populations, harms, grades, denominators and exposure	Proposal: Obtain original safety populations, group-specific events, exposure, grades, discontinuation and denominators.
23	Partly verified	Full text not readStored summary read	N23 · Supplementary harm evidenceWas the scope of descriptive safety comparisons and no planned inferential testing retained?Required	The preserved summary states that more harms were described in the PEGPH20 group and that the protocol did not plan inferential testing. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Descriptive differences are not promoted into statistically significant harm or confirmed causality, and absence of testing is not interpreted as safety.	Prespecified safety plans, descriptive tables, relatedness and testing materials	Proposal: Obtain original safety plans, data collection, relatedness and group-specific descriptive tables.
24	Partly verified	Full text not readStored summary read	N24 · Supplementary harm evidenceAre thrombosis-prophylaxis conditions and gaps in original harm events distinguished?Required	The historical research condition of mandatory enoxaparin prophylaxis in both groups is preserved. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not create original thrombosis-event counts, CI or effects. No prophylaxis or drug-adjustment instructions are given to readers, and safety is not transferred to conditions without prophylaxis.	Actual prophylaxis, thrombosis events, exposure and group-specific denominators	Proposal: Obtain original thrombosis-event, prophylactic-exposure, deviation and safety-denominator materials.
25	Unverified	Full text not readStored summary read	N25 · Supplementary harm evidenceWere gaps in other, rare or long-term harms, discontinuation and replication evidence retained?Required	The summary focuses on some severe harms and mandatory prophylaxis. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. No new certification of absence of all harms, long-term safety or independent harm replication is made. Numbers, proportions and CI beyond the original summary are absent.	All harms, discontinuation, duration, exposure and independent-report relationships	Proposal: Complete original safety tables, exposure, discontinuation and long-term or rare-harm materials are needed.
26	Unverified	Full text not readStored summary read	N26 · Supplementary harm evidenceWere other cancers, treatment lines and clinical applications not automatically extended?Required	The original materials concern untreated high-expression stage IV pancreatic ductal adenocarcinoma with shared nab-paclitaxel plus gemcitabine and mandatory prophylaxis. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not certify efficacy or harms of other cancers, treatment lines or combinations or create treatment-selection, use or substitution recommendations.	Direct effect or harm materials by population, combination and prophylaxis	Proposal: Link direct materials on new populations or combinations to separate questions.
27	Partly verified	Full text not readStored summary read	N27 · Comparative efficacyIs reading the preserved summary distinguished from reading external papers, registration, protocol or SAP?Required	The complete parent verdict summary was read for production, and the original PubMed URL and NCT02715804 are preserved. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. No new registration URL is constructed from identifiers. All external abstracts, full texts, registration and plans remain unread, and no separate external link tests were performed.	Original URLs, identifiers, individual material types and actual-reading records	Proposal: Link original materials acquired by the user to types and access states.
28	Partly verified	Full text not readStored summary read	N28 · Comparative efficacyAre original dates, Korean and English drafts, empty values, verdict and content-review states distinguished?Supplementary	2026-08-26, empty correction and deliberation values, Korean and English drafts, parent D34, original false or missing values, empty values and subclaim grade C are preserved. Original review-pending and production-eligibility markers are history. R01	Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Absent subclaim scores are not filled. Existing content review remains incomplete; activation and completion markers for model, content and boundary review are false, new units are 0 and the final independent total is not recorded.	Complete preserved summary, verdict record, original assessment axes, history and current production state	Proposal: Reflect additional materials and decisions through preservation of original wording and separate events.

No items match your search or filter.

28 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Previously untreated stage IV pancreatic ductal adenocarcinoma with stromal hyaluronan staining of at least 50%; detailed eligibility remains unread
Ingredient, formulation and route: Historical research conditions for PEGPH20 add-on therapy; distinguished from shared nab-paclitaxel, gemcitabine and mandatory enoxaparin prophylaxis
Dose: Research-drug or prophylaxis doses, schedules and actual-exposure details remain unread; no treatment or medication instructions are created
Comparator: Original comparison with matching placebo and the same shared anticancer treatment and mandatory prophylaxis
Measured outcome: Selected lower-order objective response; exploratory scope after OS failure distinguished from PFS and harms
Duration: Original median OS of 11.2/11.5 months and PFS of 7.1/7.1 months are outcome values and are not used as intervention or follow-up duration; data-cutoff and actual-exposure or follow-up details remain unread
Questions outside this scope: Transferring ORR into OS, PFS or clinical-function benefit; Certifying exploratory lower-order results as confirmatory success under fixed-sequence testing; Certifying effects or harms in other cancers, treatment lines, combinations or prophylaxis conditions; Adding different endpoints, sibling sheets or the same people as independent evidence; Drug selection, use, prophylaxis, substitution or treatment recommendations

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Van Cutsem E, Tempero MA, Sigal D, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38:3185-3194. PMID: 32706635.

PubMed

Material type: HALO109-301 randomized phase 3 trial report
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Objective response was 47% versus 36%, ratio 1.29 (95% CI 1.03 to 1.63). The fixed testing sequence required significant overall survival before lower-order confirmatory testing; after survival failed, this result must be interpreted as exploratory. Median progression-free survival was also 7.1 versus 7.1 months, HR 0.97 (95% CI 0.75 to 1.26).
Record level: Preserved-summary results; ORR is linked from the body, and original evidence-list OS values are not changed into ORR
Study overlap and independent replication: HALO109-301 shares the same report, original trial, cohort and two subclaim outcomes; OS, ORR and PFS are not counted as separate new trials. A study-family identifier links relationships and does not certify unique trial counts; reports, endpoints, sibling sheets and the same participants are not newly added as independent evidence.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
local_summary	Original source link preserved	Summary read	Summary read	Preserved parent verdict summary
abstract	Original source link preserved	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
fulltext	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
registration	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review
protocol_sap	No separate URL in the original material	Not read	Not read	External material unread; a URL does not mean acquisition, reading or completed review

Report counts versus independent study counts

HALO109-301 shares the same report, original trial, cohort and two subclaim outcomes; OS, ORR and PFS are not counted as separate new trials. A study-family identifier links relationships and does not certify unique trial counts; reports, endpoints, sibling sheets and the same participants are not newly added as independent evidence.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Are the original objective-response subclaim verdict and parent survival grade D distinguished?

Required materials and conditions: Separate records of subclaim original wording, grade, note and parent context
Conditions for verification: Separate records of subclaim original wording, grade, note and parent context
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N02 · Who was actually eligible for response-rate analysis?

Required materials and conditions: Expression, cancer type, stage, treatment line, baseline conditions and denominators
Conditions for verification: Expression, cancer type, stage, treatment line, baseline conditions and denominators
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N03 · Were added PEGPH20, matching placebo and shared anticancer treatment separated?

Required materials and conditions: Original drug, placebo, shared-treatment and actual-exposure records
Conditions for verification: Original drug, placebo, shared-treatment and actual-exposure records
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N04 · Are shared thrombosis-prophylaxis conditions and actual management scope retained?

Required materials and conditions: Prophylaxis, concomitant management, actual exposure, adherence and denominators
Conditions for verification: Prophylaxis, concomitant management, actual exposure, adherence and denominators
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N05 · Are 494 randomized participants, 492 ITT participants and response-rate denominators the same?

Required materials and conditions: Group-specific allocation, ITT, assessable-imaging and response-analysis denominators
Conditions for verification: Group-specific allocation, ITT, assessable-imaging and response-analysis denominators
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N06 · What were objective-response criteria, confirmation, times and assessors?

Required materials and conditions: Imaging criteria, response types, confirmatory assessments, times and measurement procedures
Conditions for verification: Imaging criteria, response types, confirmatory assessments, times and measurement procedures
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N07 · Were original proportions of 47% versus 36% and missing original responder counts retained?

Required materials and conditions: Original group-specific proportions, responders, denominators and aggregation rules
Conditions for verification: Original group-specific proportions, responders, denominators and aggregation rules
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N08 · Are the response ratio 1.29, CI and new tests distinguished?

Required materials and conditions: Original ratio, CI, testing, model, denominator and effect definitions
Conditions for verification: Original ratio, CI, testing, model, denominator and effect definitions
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N09 · Was the fixed sequence requiring significant survival first preserved?

Required materials and conditions: Original plans for testing sequence, alpha, endpoint hierarchy and changes
Conditions for verification: Original plans for testing sequence, alpha, endpoint hierarchy and changes
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N10 · Are the prespecified 2019 amendment, sole primary overall survival and response hierarchy distinguished?

Required materials and conditions: Registration, protocol, SAP, dates and decisions before and after amendment
Conditions for verification: Registration, protocol, SAP, dates and decisions before and after amendment
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N11 · Were exploratory response signals, clinical importance and confirmatory effects separated?

Required materials and conditions: Response importance, prespecified success thresholds, hierarchy and original CI
Conditions for verification: Response importance, prespecified success thresholds, hierarchy and original CI
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N12 · Were null overall survival and increased response preserved together?

Required materials and conditions: Original OS medians, HR, CI, P, events and denominators
Conditions for verification: Original OS medians, HR, CI, P, events and denominators
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N13 · Are null progression-free survival, response duration and progression the same outcome?

Required materials and conditions: PFS, response duration, imaging-response definitions, effects and denominators
Conditions for verification: PFS, response duration, imaging-response definitions, effects and denominators
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N14 · Were central allocation, double-blinding and imaging-assessment details separated?

Required materials and conditions: Original allocation-concealment, blinding, imaging-assessor and analyst methods
Conditions for verification: Original allocation-concealment, blinding, imaging-assessor and analyst methods
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N15 · Were gaps in missing response assessments, deviations, progression, death handling and denominators retained?

Required materials and conditions: Missing imaging assessments, analysis populations, deaths, progression and missing-data rules
Conditions for verification: Missing imaging assessments, analysis populations, deaths, progression and missing-data rules
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N16 · What gaps remain in response interpretation of actual exposure, anticancer intensity, discontinuation or subsequent treatment?

Required materials and conditions: Added drug, shared anticancer treatment, prophylaxis, crossover, discontinuation and actual exposure
Conditions for verification: Added drug, shared anticancer treatment, prophylaxis, crossover, discontinuation and actual exposure
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N17 · Were response subgroups, expression analyses and multiple outcomes verified prospectively?

Required materials and conditions: Original plans for subgroups, interactions, hierarchy, denominators and testing
Conditions for verification: Original plans for subgroups, interactions, hierarchy, denominators and testing
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N18 · Were mechanisms and imaging shrinkage not converted into clinical function or survival benefit?

Required materials and conditions: Separate materials for response, mechanisms and direct clinical function or survival
Conditions for verification: Separate materials for response, mechanisms and direct clinical function or survival
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N19 · Were the same HALO report, cohort and two endpoints not added as independent evidence?

Required materials and conditions: Relationships among original trial, report, shared participants, times and sibling sheets
Conditions for verification: Relationships among original trial, report, shared participants, times and sibling sheets
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N20 · Were Halozyme support, drug or placebo, 2 employees and Paragon writing separated?

Required materials and conditions: Cash support, products, affiliations, management and external analysis or writing roles
Conditions for verification: Cash support, products, affiliations, management and external analysis or writing roles
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N21 · Were original R1 and I0 and unverified independent replication retained?

Required materials and conditions: Relationships among manufacturer trial, funding, investigators and original verdict
Conditions for verification: Relationships among manufacturer trial, funding, investigators and original verdict
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N22 · Are grade 3 or worse harm proportions and response benefit displayed separately?

Required materials and conditions: Original group-specific safety populations, harms, grades, denominators and exposure
Conditions for verification: Original group-specific safety populations, harms, grades, denominators and exposure
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N23 · Was the scope of descriptive safety comparisons and no planned inferential testing retained?

Required materials and conditions: Prespecified safety plans, descriptive tables, relatedness and testing materials
Conditions for verification: Prespecified safety plans, descriptive tables, relatedness and testing materials
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N24 · Are thrombosis-prophylaxis conditions and gaps in original harm events distinguished?

Required materials and conditions: Actual prophylaxis, thrombosis events, exposure and group-specific denominators
Conditions for verification: Actual prophylaxis, thrombosis events, exposure and group-specific denominators
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N25 · Were gaps in other, rare or long-term harms, discontinuation and replication evidence retained?

Required materials and conditions: All harms, discontinuation, duration, exposure and independent-report relationships
Conditions for verification: All harms, discontinuation, duration, exposure and independent-report relationships
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N26 · Were other cancers, treatment lines and clinical applications not automatically extended?

Required materials and conditions: Direct effect or harm materials by population, combination and prophylaxis
Conditions for verification: Direct effect or harm materials by population, combination and prophylaxis
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N27 · Is reading the preserved summary distinguished from reading external papers, registration, protocol or SAP?

Required materials and conditions: Original URLs, identifiers, individual material types and actual-reading records
Conditions for verification: Original URLs, identifiers, individual material types and actual-reading records
Requirement and applicability: Required
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

N28 · Are original dates, Korean and English drafts, empty values, verdict and content-review states distinguished?

Required materials and conditions: Complete preserved summary, verdict record, original assessment axes, history and current production state
Conditions for verification: Complete preserved summary, verdict record, original assessment axes, history and current production state
Requirement and applicability: Supplementary
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Referenced methods: Increased objective response

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed.

What the statuses mean

Partly verified: Some information exists in the preserved review summary; detailed original materials remain unverified. This does not certify a passed review or clinical efficacy.
Unverified: Detailed materials for the selected condition could not be established within the stored scope; this does not mean zero effect, zero studies or safety
Review incomplete: Review of existing content incomplete
Met: Use only within the relevant conditions after existing content review; no automatic designation in this preparation
Not reported: Distinguish only within materials actually read; do not turn unread external materials into unreported findings
Inaccessible: Not applied during this preparation because actual access was not tested
Not applicable: Use with a reason for non-applicability based on an explicit question boundary
Conflicting data: Judge after actual material comparison; review was not performed during this preparation
Insufficient evidence for the conditions: Do not use as a clinical grade encompassing currently unread materials

Change history

2026-10-11 · Public page/material version 1.0

Public reader pages and material were prepared from the existing 28 items. No new clinical searches, verification-state changes or scoring were performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Are the original objective-response subclaim verdict and parent survival grade D distinguished?

Current findings: The selected existing claim is increased objective response, original grade C. Its note states 47% versus 36%, but no eligibility for confirmatory testing under the fixed sequence. The parent is OS D34 with Caution.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Absent subclaim scores, statuses and axes are not filled with parent values. Subclaim C is not uniformly changed to D, and no new grade is assessed.
Reason for missing information: Absent subclaim scores, statuses and axes are not filled with parent values. Subclaim C is not uniformly changed to D, and no new grade is assessed.
Required materials and conditions: Separate records of subclaim original wording, grade, note and parent context
Materials to obtain first: Absent subclaim scores, statuses and axes are not filled with parent values. Subclaim C is not uniformly changed to D, and no new grade is assessed.
Further research: Proposal: Link additional materials separately to the response question and parent survival results.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Separate records of subclaim original wording, grade, note and parent context
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N02 · Who was actually eligible for response-rate analysis?

Current findings: The original population was untreated stage IV pancreatic ductal adenocarcinoma with stromal hyaluronan staining of at least 50%.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not automatically apply this to responses at other expression levels, cancers, treatment lines or stages. Additional response-analysis eligibility and assessable populations remain unread.
Reason for missing information: Do not automatically apply this to responses at other expression levels, cancers, treatment lines or stages. Additional response-analysis eligibility and assessable populations remain unread.
Required materials and conditions: Expression, cancer type, stage, treatment line, baseline conditions and denominators
Materials to obtain first: Do not automatically apply this to responses at other expression levels, cancers, treatment lines or stages. Additional response-analysis eligibility and assessable populations remain unread.
Further research: Proposal: Obtain original eligibility, baseline tumor, biomarker and assessable analysis-population materials.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Expression, cancer type, stage, treatment line, baseline conditions and denominators
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N03 · Were added PEGPH20, matching placebo and shared anticancer treatment separated?

Current findings: The trial context of nab-paclitaxel plus gemcitabine in both groups, with added PEGPH20 versus matching placebo, is preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Original response effects are not converted into overall efficacy of shared anticancer treatment. Dose, schedule, actual exposure and discontinuation details remain unread; no treatment guidance is created.
Reason for missing information: Original response effects are not converted into overall efficacy of shared anticancer treatment. Dose, schedule, actual exposure and discontinuation details remain unread; no treatment guidance is created.
Required materials and conditions: Original drug, placebo, shared-treatment and actual-exposure records
Materials to obtain first: Original response effects are not converted into overall efficacy of shared anticancer treatment. Dose, schedule, actual exposure and discontinuation details remain unread; no treatment guidance is created.
Further research: Proposal: Obtain original intervention, placebo, shared regimen and actual-exposure materials.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original drug, placebo, shared-treatment and actual-exposure records
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N04 · Are shared thrombosis-prophylaxis conditions and actual management scope retained?

Current findings: Both groups had mandatory enoxaparin prophylaxis because of thromboembolic risk.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Research conditions are not converted into prophylactic-medication instructions for readers. Response or safety results are not automatically applied to other conditions without prophylaxis.
Reason for missing information: Research conditions are not converted into prophylactic-medication instructions for readers. Response or safety results are not automatically applied to other conditions without prophylaxis.
Required materials and conditions: Prophylaxis, concomitant management, actual exposure, adherence and denominators
Materials to obtain first: Research conditions are not converted into prophylactic-medication instructions for readers. Response or safety results are not automatically applied to other conditions without prophylaxis.
Further research: Proposal: Obtain original shared-management, prophylactic-exposure, deviation and group-specific event materials.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Prophylaxis, concomitant management, actual exposure, adherence and denominators
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N05 · Are 494 randomized participants, 492 ITT participants and response-rate denominators the same?

Current findings: 494 participants randomized 2:1 and 492 ITT participants are overall trial information.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. 492 is not certified as a response-analysis denominator that was not directly given. Group-specific denominators and responder counts are not back-calculated from proportions.
Reason for missing information: 492 is not certified as a response-analysis denominator that was not directly given. Group-specific denominators and responder counts are not back-calculated from proportions.
Required materials and conditions: Group-specific allocation, ITT, assessable-imaging and response-analysis denominators
Materials to obtain first: 492 is not certified as a response-analysis denominator that was not directly given. Group-specific denominators and responder counts are not back-calculated from proportions.
Further research: Proposal: Obtain original group allocation, response-analysis populations, assessable counts and original responder tables.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Group-specific allocation, ITT, assessable-imaging and response-analysis denominators
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N06 · What were objective-response criteria, confirmation, times and assessors?

Current findings: The preserved summary records objective imaging response as a separate lower-order outcome.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. RECIST version, central or institutional assessment, complete or partial response, confirmation schedules and classification methods are absent from the summary and are not created.
Reason for missing information: RECIST version, central or institutional assessment, complete or partial response, confirmation schedules and classification methods are absent from the summary and are not created.
Required materials and conditions: Imaging criteria, response types, confirmatory assessments, times and measurement procedures
Materials to obtain first: RECIST version, central or institutional assessment, complete or partial response, confirmation schedules and classification methods are absent from the summary and are not created.
Further research: Proposal: Obtain original response definitions, assessment procedures, assessors, schedules and classification tables.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Imaging criteria, response types, confirmatory assessments, times and measurement procedures
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N07 · Were original proportions of 47% versus 36% and missing original responder counts retained?

Current findings: Objective response of 47% versus 36% is recorded in the original summary body.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not calculate new proportion differences, responder counts, NNT or RR. Group labels, original denominators and missing-assessment handling details remain unread.
Reason for missing information: Do not calculate new proportion differences, responder counts, NNT or RR. Group labels, original denominators and missing-assessment handling details remain unread.
Required materials and conditions: Original group-specific proportions, responders, denominators and aggregation rules
Materials to obtain first: Do not calculate new proportion differences, responder counts, NNT or RR. Group labels, original denominators and missing-assessment handling details remain unread.
Further research: Proposal: Obtain original responders, group-specific analysis denominators and aggregation rules.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original group-specific proportions, responders, denominators and aggregation rules
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N08 · Are the response ratio 1.29, CI and new tests distinguished?

Current findings: The original response ratio is 1.29 (95% CI 1.03 to 1.63).
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not recalculate from 47/36 or create the ratio model, new P, exact tests, adjustment variables or inferential eligibility.
Reason for missing information: Do not recalculate from 47/36 or create the ratio model, new P, exact tests, adjustment variables or inferential eligibility.
Required materials and conditions: Original ratio, CI, testing, model, denominator and effect definitions
Materials to obtain first: Do not recalculate from 47/36 or create the ratio model, new P, exact tests, adjustment variables or inferential eligibility.
Further research: Proposal: Obtain original ratio definitions, models, intervals, denominators and testing plans.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original ratio, CI, testing, model, denominator and effect definitions
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N09 · Was the fixed sequence requiring significant survival first preserved?

Current findings: The preserved summary states that overall survival had to be significant first for lower-order confirmatory testing, and response must be interpreted as exploratory after survival failed.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Exclusion of 1 by the CI alone does not promote response into prespecified confirmatory success.
Reason for missing information: Exclusion of 1 by the CI alone does not promote response into prespecified confirmatory success.
Required materials and conditions: Original plans for testing sequence, alpha, endpoint hierarchy and changes
Materials to obtain first: Exclusion of 1 by the CI alone does not promote response into prespecified confirmatory success.
Further research: Proposal: Obtain original SAP, fixed sequence, alpha, testing and outcome lists.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original plans for testing sequence, alpha, endpoint hierarchy and changes
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N10 · Are the prespecified 2019 amendment, sole primary overall survival and response hierarchy distinguished?

Current findings: The summary records OS as the sole primary endpoint after the prespecified 2019 amendment and states agreement with NCT02715804.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Response is not newly designated as coprimary. Earlier hierarchy, amendment circumstances and actual registration content remain unread.
Reason for missing information: Response is not newly designated as coprimary. Earlier hierarchy, amendment circumstances and actual registration content remain unread.
Required materials and conditions: Registration, protocol, SAP, dates and decisions before and after amendment
Materials to obtain first: Response is not newly designated as coprimary. Earlier hierarchy, amendment circumstances and actual registration content remain unread.
Further research: Proposal: Obtain original registration history, amendment events, protocol and SAP separately.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Registration, protocol, SAP, dates and decisions before and after amendment
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N11 · Were exploratory response signals, clinical importance and confirmatory effects separated?

Current findings: The preserved summary recognizes improved response itself while stating that it is not a confirmatory conclusion or equivalent to survival benefit.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not create clinical-importance thresholds, confirmatory response success or universal treatment benefit absent from the original summary.
Reason for missing information: Do not create clinical-importance thresholds, confirmatory response success or universal treatment benefit absent from the original summary.
Required materials and conditions: Response importance, prespecified success thresholds, hierarchy and original CI
Materials to obtain first: Do not create clinical-importance thresholds, confirmatory response success or universal treatment benefit absent from the original summary.
Further research: Proposal: Obtain original planned importance, response maintenance, clinical links and hierarchy.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Response importance, prespecified success thresholds, hierarchy and original CI
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N12 · Were null overall survival and increased response preserved together?

Current findings: For 492 ITT participants, OS of 11.2 versus 11.5 months, HR 1.00 (95% CI 0.80 to 1.27), P=.97 and 330 deaths are preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Imaging response is not transferred into prolonged OS. The original context that the OS CI retained possible benefit is also not erased.
Reason for missing information: Imaging response is not transferred into prolonged OS. The original context that the OS CI retained possible benefit is also not erased.
Required materials and conditions: Original OS medians, HR, CI, P, events and denominators
Materials to obtain first: Imaging response is not transferred into prolonged OS. The original context that the OS CI retained possible benefit is also not erased.
Further research: Proposal: Obtain original OS models, curves, censoring, group-specific events and denominators separately.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original OS medians, HR, CI, P, events and denominators
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N13 · Are null progression-free survival, response duration and progression the same outcome?

Current findings: Median PFS of 7.1 versus 7.1 months, HR 0.97 (95% CI 0.75 to 1.26), is preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Positive response is not converted into PFS or response-duration benefit. Response duration, progression times and PFS P remain unread.
Reason for missing information: Positive response is not converted into PFS or response-duration benefit. Response duration, progression times and PFS P remain unread.
Required materials and conditions: PFS, response duration, imaging-response definitions, effects and denominators
Materials to obtain first: Positive response is not converted into PFS or response-duration benefit. Response duration, progression times and PFS P remain unread.
Further research: Proposal: Obtain original PFS, response-duration, persistence and progression definitions and tables.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: PFS, response duration, imaging-response definitions, effects and denominators
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N14 · Were central allocation, double-blinding and imaging-assessment details separated?

Current findings: Central interactive-response-system allocation and double-blinding with matching placebo appear in the preserved summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. This information alone does not constitute new verification of central imaging assessment, independent assessors or analyst blinding.
Reason for missing information: This information alone does not constitute new verification of central imaging assessment, independent assessors or analyst blinding.
Required materials and conditions: Original allocation-concealment, blinding, imaging-assessor and analyst methods
Materials to obtain first: This information alone does not constitute new verification of central imaging assessment, independent assessors or analyst blinding.
Further research: Proposal: Obtain original allocation, imaging-assessment, blinding roles and unblinding procedures.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original allocation-concealment, blinding, imaging-assessor and analyst methods
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N15 · Were gaps in missing response assessments, deviations, progression, death handling and denominators retained?

Current findings: Overall ITT information and original response proportions exist, but detailed response-assessment data flow is absent from the summary.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Proportions alone do not establish complete imaging for all patients, death or progression handling or ITT response rules.
Reason for missing information: Proportions alone do not establish complete imaging for all patients, death or progression handling or ITT response rules.
Required materials and conditions: Missing imaging assessments, analysis populations, deaths, progression and missing-data rules
Materials to obtain first: Proportions alone do not establish complete imaging for all patients, death or progression handling or ITT response rules.
Further research: Proposal: Obtain original assessable populations, reasons for missing assessments, death or progression handling, missing-data handling and sensitivity materials.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Missing imaging assessments, analysis populations, deaths, progression and missing-data rules
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N16 · What gaps remain in response interpretation of actual exposure, anticancer intensity, discontinuation or subsequent treatment?

Current findings: Historical intervention, shared anticancer treatment and mandatory prophylaxis conditions are preserved.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not newly calculate responder-specific exposure, dose intensity, discontinuation or subsequent-treatment effects absent from the original summary.
Reason for missing information: Do not newly calculate responder-specific exposure, dose intensity, discontinuation or subsequent-treatment effects absent from the original summary.
Required materials and conditions: Added drug, shared anticancer treatment, prophylaxis, crossover, discontinuation and actual exposure
Materials to obtain first: Do not newly calculate responder-specific exposure, dose intensity, discontinuation or subsequent-treatment effects absent from the original summary.
Further research: Proposal: Obtain original exposure, discontinuation, subsequent management and prespecified effect-of-interest materials.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Added drug, shared anticancer treatment, prophylaxis, crossover, discontinuation and actual exposure
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N17 · Were response subgroups, expression analyses and multiple outcomes verified prospectively?

Current findings: The selected population's staining threshold of at least 50% and lower-order response plans are preserved in the summary.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. No additional expression strata, treatment lines, subgroup response counts, P or independent success are created.
Reason for missing information: No additional expression strata, treatment lines, subgroup response counts, P or independent success are created.
Required materials and conditions: Original plans for subgroups, interactions, hierarchy, denominators and testing
Materials to obtain first: No additional expression strata, treatment lines, subgroup response counts, P or independent success are created.
Further research: Proposal: Obtain original subgroup, biomarker, interaction, multiplicity and effect materials.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original plans for subgroups, interactions, hierarchy, denominators and testing
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N18 · Were mechanisms and imaging shrinkage not converted into clinical function or survival benefit?

Current findings: The preserved summary explicitly states that imaging response must not be promoted into survival benefit.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Mechanistic, pain, quality-of-life, independent-living or mortality benefits are not filled in from response rates. These direct values are absent from the summary.
Reason for missing information: Mechanistic, pain, quality-of-life, independent-living or mortality benefits are not filled in from response rates. These direct values are absent from the summary.
Required materials and conditions: Separate materials for response, mechanisms and direct clinical function or survival
Materials to obtain first: Mechanistic, pain, quality-of-life, independent-living or mortality benefits are not filled in from response rates. These direct values are absent from the summary.
Further research: Proposal: Obtain direct endpoints, effects and denominators separately for clinical-function, symptom and survival questions.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Separate materials for response, mechanisms and direct clinical function or survival
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N19 · Were the same HALO report, cohort and two endpoints not added as independent evidence?

Current findings: The two sheets share one HALO109-301 literature record, NCT02715804 and the 494/492-participant context.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Response, OS, PFS and sibling sheets are not added as new independent trials or participants. Final independent and total-participant counts remain unrecorded.
Reason for missing information: Response, OS, PFS and sibling sheets are not added as new independent trials or participants. Final independent and total-participant counts remain unrecorded.
Required materials and conditions: Relationships among original trial, report, shared participants, times and sibling sheets
Materials to obtain first: Response, OS, PFS and sibling sheets are not added as new independent trials or participants. Final independent and total-participant counts remain unrecorded.
Further research: Proposal: Link new reports to existing trial and registration identifiers and relationships.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Relationships among original trial, report, shared participants, times and sibling sheets
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N20 · Were Halozyme support, drug or placebo, 2 employees and Paragon writing separated?

Current findings: Halozyme sponsorship and support, protocol, drug or placebo, data management, 2 company authors and Paragon medical writing paid by Halozyme are preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Paragon writing is not converted into outsourced analysis. Employee identities, statistical-analysis and data-access role details remain unread.
Reason for missing information: Paragon writing is not converted into outsourced analysis. Employee identities, statistical-analysis and data-access role details remain unread.
Required materials and conditions: Cash support, products, affiliations, management and external analysis or writing roles
Materials to obtain first: Paragon writing is not converted into outsourced analysis. Employee identities, statistical-analysis and data-access role details remain unread.
Further research: Proposal: Obtain each support, supply, affiliation, analysis, management and writing disclosure.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Cash support, products, affiliations, management and external analysis or writing roles
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N21 · Were original R1 and I0 and unverified independent replication retained?

Current findings: Parent R1 and I0 and the original wording that the confirmed efficacy trial was one manufacturer development trial are retained.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Positive response or two outcomes do not certify independent replication by other investigators or funding sources.
Reason for missing information: Positive response or two outcomes do not certify independent replication by other investigators or funding sources.
Required materials and conditions: Relationships among manufacturer trial, funding, investigators and original verdict
Materials to obtain first: Positive response or two outcomes do not certify independent replication by other investigators or funding sources.
Further research: Proposal: Link study, funding, author and denominator relationships of additional materials separately.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Relationships among manufacturer trial, funding, investigators and original verdict
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N22 · Are grade 3 or worse harm proportions and response benefit displayed separately?

Current findings: Original grade 3 or worse proportions are preserved: fatigue 16.0% versus 9.6%, muscle spasms 6.5% versus 0.6% and hyponatremia 8.0% versus 3.8%.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not create responder-specific harm counts, new differences, RR, CI or P. Safety-analysis denominators, periods and relatedness remain unread.
Reason for missing information: Do not create responder-specific harm counts, new differences, RR, CI or P. Safety-analysis denominators, periods and relatedness remain unread.
Required materials and conditions: Original group-specific safety populations, harms, grades, denominators and exposure
Materials to obtain first: Do not create responder-specific harm counts, new differences, RR, CI or P. Safety-analysis denominators, periods and relatedness remain unread.
Further research: Proposal: Obtain original safety populations, group-specific events, exposure, grades, discontinuation and denominators.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original group-specific safety populations, harms, grades, denominators and exposure
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N23 · Was the scope of descriptive safety comparisons and no planned inferential testing retained?

Current findings: The preserved summary states that more harms were described in the PEGPH20 group and that the protocol did not plan inferential testing.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Descriptive differences are not promoted into statistically significant harm or confirmed causality, and absence of testing is not interpreted as safety.
Reason for missing information: Descriptive differences are not promoted into statistically significant harm or confirmed causality, and absence of testing is not interpreted as safety.
Required materials and conditions: Prespecified safety plans, descriptive tables, relatedness and testing materials
Materials to obtain first: Descriptive differences are not promoted into statistically significant harm or confirmed causality, and absence of testing is not interpreted as safety.
Further research: Proposal: Obtain original safety plans, data collection, relatedness and group-specific descriptive tables.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Prespecified safety plans, descriptive tables, relatedness and testing materials
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N24 · Are thrombosis-prophylaxis conditions and gaps in original harm events distinguished?

Current findings: The historical research condition of mandatory enoxaparin prophylaxis in both groups is preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not create original thrombosis-event counts, CI or effects. No prophylaxis or drug-adjustment instructions are given to readers, and safety is not transferred to conditions without prophylaxis.
Reason for missing information: Do not create original thrombosis-event counts, CI or effects. No prophylaxis or drug-adjustment instructions are given to readers, and safety is not transferred to conditions without prophylaxis.
Required materials and conditions: Actual prophylaxis, thrombosis events, exposure and group-specific denominators
Materials to obtain first: Do not create original thrombosis-event counts, CI or effects. No prophylaxis or drug-adjustment instructions are given to readers, and safety is not transferred to conditions without prophylaxis.
Further research: Proposal: Obtain original thrombosis-event, prophylactic-exposure, deviation and safety-denominator materials.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Actual prophylaxis, thrombosis events, exposure and group-specific denominators
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N25 · Were gaps in other, rare or long-term harms, discontinuation and replication evidence retained?

Current findings: The summary focuses on some severe harms and mandatory prophylaxis.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. No new certification of absence of all harms, long-term safety or independent harm replication is made. Numbers, proportions and CI beyond the original summary are absent.
Reason for missing information: No new certification of absence of all harms, long-term safety or independent harm replication is made. Numbers, proportions and CI beyond the original summary are absent.
Required materials and conditions: All harms, discontinuation, duration, exposure and independent-report relationships
Materials to obtain first: No new certification of absence of all harms, long-term safety or independent harm replication is made. Numbers, proportions and CI beyond the original summary are absent.
Further research: Proposal: Complete original safety tables, exposure, discontinuation and long-term or rare-harm materials are needed.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: All harms, discontinuation, duration, exposure and independent-report relationships
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N26 · Were other cancers, treatment lines and clinical applications not automatically extended?

Current findings: The original materials concern untreated high-expression stage IV pancreatic ductal adenocarcinoma with shared nab-paclitaxel plus gemcitabine and mandatory prophylaxis.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Do not certify efficacy or harms of other cancers, treatment lines or combinations or create treatment-selection, use or substitution recommendations.
Reason for missing information: Do not certify efficacy or harms of other cancers, treatment lines or combinations or create treatment-selection, use or substitution recommendations.
Required materials and conditions: Direct effect or harm materials by population, combination and prophylaxis
Materials to obtain first: Do not certify efficacy or harms of other cancers, treatment lines or combinations or create treatment-selection, use or substitution recommendations.
Further research: Proposal: Link direct materials on new populations or combinations to separate questions.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Direct effect or harm materials by population, combination and prophylaxis
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N27 · Is reading the preserved summary distinguished from reading external papers, registration, protocol or SAP?

Current findings: The complete parent verdict summary was read for production, and the original PubMed URL and NCT02715804 are preserved.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. No new registration URL is constructed from identifiers. All external abstracts, full texts, registration and plans remain unread, and no separate external link tests were performed.
Reason for missing information: No new registration URL is constructed from identifiers. All external abstracts, full texts, registration and plans remain unread, and no separate external link tests were performed.
Required materials and conditions: Original URLs, identifiers, individual material types and actual-reading records
Materials to obtain first: No new registration URL is constructed from identifiers. All external abstracts, full texts, registration and plans remain unread, and no separate external link tests were performed.
Further research: Proposal: Link original materials acquired by the user to types and access states.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Original URLs, identifiers, individual material types and actual-reading records
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01

N28 · Are original dates, Korean and English drafts, empty values, verdict and content-review states distinguished?

Current findings: 2026-08-26, empty correction and deliberation values, Korean and English drafts, parent D34, original false or missing values, empty values and subclaim grade C are preserved. Original review-pending and production-eligibility markers are history.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials remain unread and existing content review remains incomplete. Absent subclaim scores are not filled. Existing content review remains incomplete; activation and completion markers for model, content and boundary review are false, new units are 0 and the final independent total is not recorded.
Reason for missing information: Absent subclaim scores are not filled. Existing content review remains incomplete; activation and completion markers for model, content and boundary review are false, new units are 0 and the final independent total is not recorded.
Required materials and conditions: Complete preserved summary, verdict record, original assessment axes, history and current production state
Materials to obtain first: Absent subclaim scores are not filled. Existing content review remains incomplete; activation and completion markers for model, content and boundary review are false, new units are 0 and the final independent total is not recorded.
Further research: Proposal: Reflect additional materials and decisions through preservation of original wording and separate events.
Remaining uncertainty: Unread/unverified does not mean zero effect, zero events, safety or new clinical certification.
Conditions for verification: Complete preserved summary, verdict record, original assessment axes, history and current production state
Why this condition is needed: Individual application conditions documenting the selected endpoint, original values, denominators, hierarchy and applicability boundaries
Application exceptions: Externally unread materials, other endpoints or out-of-scope results do not replace condition fulfillment, zero effect or safety.
Referenced methods: Increased objective response

Related sources R01